Regeneus Ltd. (AU:CMB) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Cambium Bio Limited has received Fast Track designation from the FDA for Elate Ocular, a promising treatment for moderate to severe dry eye disease. This designation could expedite the drug’s development and review process, potentially bringing it to market sooner. The company’s Phase 3 trials are expected to begin in the second quarter of 2025.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.